Financials
Financial year 2025
Revenue
€ 1.6 million
Profit
Healthy€ 517,589
▼ 80% vs 2024
Debts
Low€ 414,335
▼ 76% vs 2024
DERMAX from Liège, company number BE0667730677, closed financial year 2025 with a result of € 517,589 after tax. For that financial year DERMAX recorded revenue of € 1.6 million and equity of € 5.3 million. Compared with financial year 2024, the result moved from € 2.6 million to € 517,589. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2026.
What happened at DERMAX?
What happened at DERMAX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 517,589 (▼ 80% vs 2024). Source: NBB ↗
- Jacobsen Management SRL stepped down as director. NBB
- SVR Management SRL stepped down as director. NBB
- Jacobsen Management SRL became a director. NBB
- SVR Management SRL became a director. NBB
- New establishment in Liège. KBO
- Start of the company according to the CBE. KBO
In short
From € 194,917 loss in 2021 to € 517,589 profit in 2025.
Paid € 494,711 in corporate taxes since 2021.
Best year ever: 2024, with € 2.6 million profit.
A new publication or filing at DERMAX? We notify you, reason included.
Follow DERMAXNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Director · represented by Thomas Jacobsen
Also active at: Hyloris Developments, Hyloris, Hyloris Pharmaceuticals
since 2020 · until 2026
Managing director · represented by Stijn Van Rompay
Also active at: Hyloris Developments, Hyloris, Hyloris Pharmaceuticals
since 2020 · until 2026
Establishments
Establishment units
Physical locations of this company
Boulevard de Patience et Beaujonc 3 box 1
4000 Liège
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 23 companies are registered at this address.
Hyloris Developments same network
€ 5.1 million revenue · 2025
ONCORADIOMICS
€ 2.4 million gross margin · 2025
Hyloris same network
€ 384,852 revenue · 2025
Hyloris Pharmaceuticals same network
€ 3.8 million revenue · 2025
Hirundo Biosciences
€ 0 revenue · 2025
+18 more
Details
- Company number
- 0667.730.677
- VAT number
- BE 0667.730.677
- Registered office
- Boulevard de Patience et Beaujonc 3 bus 1, 4000 Liège
- Names & denominations
- DERMAX
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 15 December 2016
- Peppol
- Active · Active since 21 Oct 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Vervaardiging van farmaceutische grondstoffen